^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LX-086

    i
    Other names: LX-086
    Company:
    Luoxin Pharma
    Drug class:
    PIK3CA inhibitor
    Related drugs:
    4years
    [VIRTUAL] Preclinical evaluation of LX-086, a small molecule as a selective inhibitor of PI3K. (ASCO 2020)
    The selectivity of LX-086 in PI3Kα over PI3Kβ/δ/γ is similar with that of alpelisib, which had been approved by FDA in 2019. We have identified a novel potent and safe PI3Kα inhibitor LX-086. Preclinical studies show antitumor efficacy of LX-086 in PIK3CA mutant and amplified solid cancer models. LX-086 represents a promising clinical candidate for the treatment of solid cancers with PIK3CA mutation or amplification.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 amplification • PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E110K
    |
    Piqray (alpelisib) • LX-086